Estamos no ar no ! Saiba mais

Cumberland Pharmaceuticals

CPIX

Valor de mercado US$ 108 mi

7,18 USD

-0,36

4,77%

No fechamento Atualizado 16 de out. 16:00 EDT

1 dia

-4,77%

5 dias

7,65%

1 mês

2,87%

3 meses

-6,27%

6 meses

132,36%

No acumulado do ano

80,4%

1 ano

108,12%

5 anos

160,14%

10 anos

47,43%

Sobre: Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.

Funcionários: 93

Saúde Fabricantes de medicamentos — especializados e genéricos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 16,7%

Neutro 66,7%

Negativo 16,7%

Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity

Cumberland Pharmaceuticals Inc. has transformed from a commercial-stage pharma to a pre-revenue, Phase 2-stage biotech focused on rare diseases. Recent $100M asset sale to Apotex funds operations and pipeline, with a special dividend paid to shareholders and four late-stage clinical programs retained. All pipeline assets are based on ifetroban, targeting high-value indications like DMD cardiomyopathy, cancer metastasis, systemic sclerosis, and IPF.

Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

Cumberland Pharmaceuticals NASDAQ: CPIX reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to Apotex Health.

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful closing of its Strategic Transaction with Apotex Health.

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Zacks Investment Research

Possible Generic Drug Tariffs and 2 Microcaps

Generic drug tariffs could impact ELTP and CPIX.

Possible Generic Drug Tariffs and 2 Microcaps

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company update with second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Zacks Investment Research

ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?

Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.

ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Record Date is July 10, 2026 & Payment Date is July 31,2026 Corporate and Insider Share Purchase Initiatives to Continue NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company's common stock.

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

$100 million Transaction Follows Cumberland Shareholder Approval Strengthens Cumberland's Focus on Rare Disease Pipeline NASHVILLE, Tenn., July 1, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. biopharmaceutical company, today announced the closing on an agreement with subsidiary of Apotex Health Corp. ("Apotex"), the largest Canadian-based pharmaceutical company, to integrate their branded U.S. businesses.

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients NASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, today shared updated results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy (PPMD) conference in Orlando, Florida.

Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™